Boston Bio Systems Ltd
₹ 7.01
0.14%
12 Dec
- close price
About
Incorporated in 1995, Boston Bio Systems
Ltd is in the business of trading in goods
e.g. Medical equipment, testing kits,
instruments etc.[1]
Key Points
- Market Cap ₹ 4.91 Cr.
- Current Price ₹ 7.01
- High / Low ₹ 22.0 / 6.53
- Stock P/E
- Book Value ₹ 8.54
- Dividend Yield 0.00 %
- ROCE -5.89 %
- ROE -8.91 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.82 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 2.14%
- Company has a low return on equity of -3.58% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 5,533 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.12 | 0.15 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.00 | 0.19 | 0.61 | |
| 0.02 | 0.27 | 0.16 | 0.05 | 0.06 | 1.50 | 0.53 | 0.70 | 0.00 | 0.00 | 0.14 | 0.74 | 0.97 | |
| Operating Profit | -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | -0.36 |
| OPM % | -125.00% | -6.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -289.47% | -59.02% | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | -0.44 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||||
| -0.02 | -0.15 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.55 | -0.46 | |
| EPS in Rs | -0.03 | -0.21 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 | -0.79 | -0.65 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -207% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -4% |
| Last Year: | -9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
| Reserves | -0.24 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.41 | -0.41 | -0.55 | -1.10 | -1.02 |
| 1.14 | 0.14 | 0.12 | 0.12 | 0.12 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 5.44 | 4.77 | |
| 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 1.46 | 1.90 | 2.60 | 3.11 | 3.11 | 3.25 | 3.57 | 4.52 | |
| Total Liabilities | 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 15.27 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 15.27 | |
| Total Assets | 7.90 | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 15.27 |
Cash Flows
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 1.00 | 0.00 | 0.00 | 0.97 | -0.03 | -0.02 | 0.13 | 0.00 | 0.00 | 0.00 | -4.59 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.91 | 0.00 | 0.00 | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.58 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | -0.03 | -0.02 | 0.05 | 0.00 | 0.00 | 0.00 | -0.01 |
Ratios
Figures in Rs. Crores
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | 1,308.79 | 5,532.63 | ||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 11.59 | |||||||
| Days Payable | 1,488.97 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 362.57 | 1,342.92 | -168.60 | 5,532.63 | ||||
| Working Capital Days | -425.83 | -292.00 | -876.00 | 4,745.00 | 226.30 | 661.13 | 453.64 | 10,585.00 | ||||
| ROCE % | -0.25% | -2.05% | -0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.89% | -5.89% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change of Company Name
27 Nov - Name changed from Boston Bio Systems Limited to Boston Commerce Limited; certificate dated 27 Nov 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Intimitation under Regulation 47 for the publication of quarter and half year ended 30th September 2025.
-
Considered And Approved The Standalone Un-Audited Financial Results Of The Company For The Quarter And Half Ended On 30Th September, 2025.
14 Nov - Approved Q2/H1 FY2025-26 unaudited results (₹24.47L revenue; ₹10.62L H1 PBT); appointed auditors.
-
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 Held Today I.E. 14Th November, 2025
14 Nov - Board approved unaudited Q2/H1 results (30 Sep 2025); appointed secretarial and internal auditors on 14 Nov 2025.
-
Board Meeting Intimation for Prior Intimation Of Date Of Board Meeting For Considering The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2025.
7 Nov - Board meeting on 14 Nov 2025 to approve unaudited Q2 and H1 results for September 30, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2000
from bse
-
Financial Year 1999
from bse
Business Overview:[1]
BBSL specializes in jobwork for herbal and health-related products for formulation companies. Company also has plans to enter the medical field which includes the sales and servicing of medical equipment